Announcements

Sativa begins cannabinoid research with King’s College London
Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, has entered into a research agreement with King’s College London (“the College”) to research the impact of cannabinoids on inflammation and respiratory diseases.
Sativa’s PhytoVista Laboratories’ 1000th cannabinoid and terpenes test and two new hires
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this…
Appointment of Director of Regulatory affairs
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this…
Sativa hires retail expert Chris Jones to launch Sativa’s Goodbody & Blunt wellness centres
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this…
Sativa Investments 'at the forefront' of developing UK medical cannabis market
Geremy Thomas, founder and chief executive of Sativa Investments PLC (LON:SATI), caught up with Proactive London’s Andrew Scott to discuss the NEX-based medical cannabis investor’s trading and strategic update.
Strategic and Trading Update
Press Release 8th January 2019 The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the…
Investee business Rapid Dose Therapeutics lists on the Canadian Securities Exchange
Press Release 18 December 2018 The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via…
Dr Brown appointed to Advisory Board
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this…
Share Option Scheme
Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, announces that the Company has adopted the Sativa Investments PLC Share Plan (the “Scheme”), to recognise the work accomplished by the Sativa team
Option agreement on 298,806 sq ft glasshouse signed
Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, has now signed the option agreement to lease a 7.53 acre site for medicinal cannabis production in Wiltshire on which the Company intends to…
Change in Board responsibilities
Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, announces that Mark Blower, currently an Executive Director of the Company, is moving to a non-Executive Director role with immediate effect.
Heads of Terms for an option to lease a 7.53 acre UK site for medicinal cannabis production
Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, has signed Heads of Terms for an £85K option to lease a 7.53 acre development site in Wiltshire.
Sativa Investments Share Placing
Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, is pleased to announce that it has raised £3.75 million (before expenses) by way of a placing of 62,500,000 new ordinary shares of 0.25p…
Sativa Half Year Financial Results (Unaudited) June 2018
Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, is pleased to announce its half year results for the six months ended 30 June 2018.
Medicinal cannabis group Sativa enters joint venture with Lexamed GmbH
Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, has established a joint venture with German-based Lexamed GmbH (“Lexamed”), forming a new German medicinal cannabis company named Sativa Germany GmbH
Sativa appoints Chief Financial Officer and Director
Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, has appointed Joseph Colliver FCA as Chief Financial Officer and a Director of the Company.
Directors’ appointments/resignation
Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, has appointed Jonathan Peter Wearing as an independent non-executive director and Angus Jeremy Kerr as a non-executive director of the Company.
Sativa signs IP agreement with Canadian-based Veritas Pharma Inc.
Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, has signed an IP sharing agreement with Canadian-based emerging global pharmaceutical company Veritas Pharma Inc. (“Veritas” or “Veritas Pharma”) in which the Company invested…
Sativa agrees to the 100% purchase of PhytoVista Laboratories
Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, has agreed to purchase, for £435,000, 100 per cent of PhytoVista Laboratories (“PhytoVista”), a UK-based laboratory that tests CBD oils and hemp products.
Dealing Arrangements
The Board of Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, is aware of the exceptional and growing demand amongst investors to own shares in the Company. As announced on the Company’s…
Share Placing completed to Miton Asset Management
Sativa Investments PLC (NEX:SATI), the UK’s first medicinal cannabis investment vehicle, announces that the share Placing of 12,500,000 new Ordinary Shares at a subscription price of 4 pence per share announced on Wednesday 27 June, raising…